As a clinical-stage biotech with no revenue, the key catalysts are pipeline milestones and regulatory updates. Monitor for upcoming data readouts or partnership announcements, as these are the primary drivers for the stock. The current cash position provides a runway into 2027, reducing near-term financing risk.
Price Chart
Executive Summary
Spero Therapeutics reported Q2 2026 financial results, highlighting a net loss of $11.0 million for the quarter, compared to a net loss of $10.7 million in the same period last year. The company ended the quarter with $60.7 million in cash, cash equivalents, and marketable securities, providing a runway into 2027. The results are largely neutral for a clinical-stage biotech with no approved products, as the focus remains on pipeline development rather than financial performance.
Key Financial Metrics
Key Facts
- Net loss of $11.0 million for Q2 2026, compared to $10.7 million in Q2 2025.
- Cash, cash equivalents, and marketable securities of $60.7 million as of June 30, 2026.
- Research and development expenses were $7.5 million for Q2 2026, down from $8.5 million in Q2 2025.
- General and administrative expenses were $4.2 million for Q2 2026, compared to $4.0 million in Q2 2025.
- No revenue was reported for the quarter, consistent with the company's clinical-stage status.
Financial Impact
Net loss of $11.0 million, with cash runway into 2027.
Risk Factors
- Clinical trial failures or delays could significantly impact the stock.
- Need for future capital raises to fund operations beyond current cash runway.
- No approved products or revenue streams, making the company entirely dependent on pipeline success.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3344036 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | EFFECT | $1.13 $1.13 | · 0.00% | ▼ −0.34% | $1.20 (−5.75%) |
Aug 28, 2026 4w ago | 8-K | $1.22 $1.19 | ▲ +2.46% | ▲ +2.32% | $1.20 (+2.05%) |
Aug 28, 2026 4w ago | S-3 | $1.22 $1.19 | ▲ +2.46% | ▲ +2.32% | $1.20 (+2.05%) |
Aug 12, 2026 7w ago | Press Release | $1.24 $1.22 | ▼ −1.61% | ▲ +0.35% | $1.20 (−3.63%) |
Jul 14, 2026 11w ago | 8-K | $1.70 $1.44 | ▼ −15.29% | ▼ −14.00% | $1.20 (−29.71%) |
Jul 14, 2026 11w ago | Press Release | $1.70 $1.44 | ▼ −15.29% | ▼ −14.00% | $1.20 (−29.71%) |
Jun 25, 2026 14w ago | 8-K | $2.26 $2.20 | ▼ −2.65% | ▼ −4.82% | $1.20 (−47.12%) |
Jun 22, 2026 14w ago | 8-K | $2.15 $2.26 | ▲ +5.12% | ▲ +4.10% | $1.20 (−44.42%) |
Jun 17, 2026 15w ago | Press Release | $2.11 $2.10 | ▼ −0.47% | ▲ +0.57% | $1.20 (−43.36%) |
May 13, 2026 20w ago | 8-K | $2.76 $2.69 | ▼ −2.54% | ▼ −1.82% | $1.20 (−56.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access